Of them, monoclonal antibodies (mAbs) that block the interaction of PCSK9/LDLR appear to be promising therapeutic agents to treat hypercholesterolemia because of their significant advantages such as being highly selective, well-tolerated and having fewer dosing frequencies [15]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.